XingHuan Pharmaceutical

Starring Pharmaceutical is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics for oncology. The company leverages its proprietary drug discovery platform to target high-value oncogenic pathways and address mechanisms of drug resistance in prevalent cancers. Its lead candidate, SH-1028, is a potent third-generation EGFR tyrosine kinase inhibitor currently in Phase 2 clinical trials for the treatment of non-small cell lung cancer. Starring Pharmaceutical is also advancing a diverse pipeline of inhibitors targeting CDK4/6 and KRAS G12C, while actively exploring novel modalities such as PROTAC technology. Supported by prominent venture capital firms, the company aims to deliver transformative medicines to patients with significant unmet medical needs globally.